Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

NCT04472598 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis (MF)

Interventions

DRUG: Placebo for Navitoclax
DRUG: Ruxolitinib
DRUG: Navitoclax

Sponsor

AbbVie